dc.creator | Reis J. | |
dc.creator | Cagide F. | |
dc.creator | Valencia M.E. | |
dc.creator | Teixeira J. | |
dc.creator | Bagetta D. | |
dc.creator | Pérez C. | |
dc.creator | Uriarte E. | |
dc.creator | Oliveira P.J. | |
dc.creator | Ortuso F. | |
dc.creator | Alcaro S. | |
dc.creator | Rodríguez-Franco M.I. | |
dc.creator | Borges F. | |
dc.date.accessioned | 2020-09-02T22:27:03Z | |
dc.date.accessioned | 2022-11-08T20:25:14Z | |
dc.date.available | 2020-09-02T22:27:03Z | |
dc.date.available | 2022-11-08T20:25:14Z | |
dc.date.created | 2020-09-02T22:27:03Z | |
dc.date.issued | 2018 | |
dc.identifier | 158, , 781-800 | |
dc.identifier | 02235234 | |
dc.identifier | https://hdl.handle.net/20.500.12728/6037 | |
dc.identifier.uri | https://repositorioslatinoamericanos.uchile.cl/handle/2250/5145578 | |
dc.language | en | |
dc.publisher | Elsevier Masson SAS | |
dc.subject | AChE inhibitors | |
dc.subject | Alzheimer's disease | |
dc.subject | Chromone | |
dc.subject | MAO-B inhibitors | |
dc.subject | Multi-target-directed ligands | |
dc.subject | New chemical entities | |
dc.subject | 2 (dimethylamino)ethyl (e) 3 [4 oxo 2 (4 methylphenlcarbamoyl) 4h chromen 6 yl]acrylate | |
dc.subject | 2 (dimethylamino)ethyl (e) 3 [4 oxo 3 (phenylcarbamoyl) 4h chromen 6 yl]acrylate | |
dc.subject | cholinesterase inhibitor | |
dc.subject | chromone derivative | |
dc.subject | monoamine oxidase inhibitor | |
dc.subject | unclassified drug | |
dc.subject | amine oxidase (flavin containing) | |
dc.subject | cholinesterase | |
dc.subject | cholinesterase inhibitor | |
dc.subject | chromone derivative | |
dc.subject | ligand | |
dc.subject | monoamine oxidase inhibitor | |
dc.subject | Alzheimer disease | |
dc.subject | Article | |
dc.subject | drug structure | |
dc.subject | drug synthesis | |
dc.subject | enzyme inhibition | |
dc.subject | IC50 | |
dc.subject | Alzheimer disease | |
dc.subject | blood brain barrier | |
dc.subject | chemistry | |
dc.subject | drug design | |
dc.subject | Hep-G2 cell line | |
dc.subject | human | |
dc.subject | metabolism | |
dc.subject | molecular docking | |
dc.subject | molecularly targeted therapy | |
dc.subject | Alzheimer Disease | |
dc.subject | Blood-Brain Barrier | |
dc.subject | Cholinesterase Inhibitors | |
dc.subject | Cholinesterases | |
dc.subject | Chromones | |
dc.subject | Drug Design | |
dc.subject | Hep G2 Cells | |
dc.subject | Humans | |
dc.subject | Ligands | |
dc.subject | Molecular Docking Simulation | |
dc.subject | Molecular Targeted Therapy | |
dc.subject | Monoamine Oxidase | |
dc.subject | Monoamine Oxidase Inhibitors | |
dc.title | Multi-target-directed ligands for Alzheimer's disease: Discovery of chromone-based monoamine oxidase/cholinesterase inhibitors | |
dc.type | Article | |